{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:57:42Z","timestamp":1791493062659,"version":"4.3.4"},"reference-count":183,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300682"],"award-info":[{"award-number":["32300682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["FRF-TP-22-007A1"],"award-info":[{"award-number":["FRF-TP-22-007A1"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities","award":["32300682"],"award-info":[{"award-number":["32300682"]}]},{"name":"Fundamental Research Funds for the Central Universities","award":["FRF-TP-22-007A1"],"award-info":[{"award-number":["FRF-TP-22-007A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>There is increasing interest in the potential therapeutic role of 5-HT (serotonin) in the treatment of neurodegenerative diseases, which are characterized by the progressive degeneration and death of nerve cells. 5-HT is a vital neurotransmitter that plays a central role in regulating mood, cognition, and various physiological processes in the body. Disruptions in the 5-HT system have been linked to several neurological and psychiatric disorders, making it an attractive target for therapeutic intervention. Although the exact causes of neurodegenerative diseases such as Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), and amyotrophic lateral sclerosis (ALS) are not fully understood, researchers believe that regulating the 5-HT system could help alleviate symptoms and potentially slow the progression of these diseases. Here, we delve into the potential of harnessing 5-HT as a therapeutic target for the treatment of neurodegenerative diseases. It is important to note that the current clinical drugs targeting 5-HT are still limited in the treatment of these complex diseases. Therefore, further research and clinical trials are needed to evaluate the feasibility and effectiveness of its clinical application.<\/jats:p>","DOI":"10.3390\/ijms252413446","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T04:14:52Z","timestamp":1734322492000},"page":"13446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"25","author":[{"given":"Cencan","family":"Xing","sequence":"first","affiliation":[{"name":"Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China"},{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China"},{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangyu","family":"Bi","sequence":"additional","affiliation":[{"name":"Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China"},{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lei","sequence":"additional","affiliation":[{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongci","family":"Hang","sequence":"additional","affiliation":[{"name":"Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China"},{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwu","family":"Du","sequence":"additional","affiliation":[{"name":"Daxing Research Institute, University of Science and Technology Beijing, Beijing 100083, China"},{"name":"School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing 100083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.neubiorev.2021.05.005","article-title":"Anxiety and Alzheimer\u2019s disease: Behavioral analysis and neural basis in rodent models of Alzheimer\u2019s-related neuropathology","volume":"127","author":"Pentkowski","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2019.09.012","article-title":"Depression and Anxiety in Parkinson Disease","volume":"36","author":"Ray","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.neuropsych.14100265","article-title":"Anxiety in Huntington\u2019s Disease","volume":"27","author":"Dale","year":"2015","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2525967","DOI":"10.1155\/2017\/2525967","article-title":"Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications","volume":"2017","author":"Liu","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0197-4580(87)90073-X","article-title":"Hypothesis on the regulation of cytosol calcium concentration and the aging brain","volume":"8","author":"Khachaturian","year":"1987","journal-title":"Neurobiol. Aging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/539179a","article-title":"Neurodegenerative diseases","volume":"539","author":"Heemels","year":"2016","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/10408398.2017.1357534","article-title":"How important is tryptophan in human health?","volume":"59","author":"Chirumbolo","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.14336\/AD.2022.0916","article-title":"Tryptophan Metabolism in Central Nervous System Diseases: Pathophysiology and Potential Therapeutic Strategies","volume":"14","author":"Huang","year":"2023","journal-title":"Aging Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12079-018-0482-2","article-title":"The 5-Hydroxytryptamine signaling map: An overview of serotonin-serotonin receptor mediated signaling network","volume":"12","author":"Sahu","year":"2018","journal-title":"J. Cell Commun. Signal."},{"key":"ref_11","first-page":"4","article-title":"Serotonin and its place in the pathogenesis of depression","volume":"49","author":"Coppen","year":"1988","journal-title":"J. Clin. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-199501004-00006","article-title":"The role of serotonin in depression and anxiety","volume":"9","author":"Baldwin","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/smrv.2001.0174","article-title":"Serotonin and sleep","volume":"6","author":"Ursin","year":"2002","journal-title":"Sleep. Med. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/FBP.0b013e328357440d","article-title":"Serotonin neurotransmission in anorexia nervosa","volume":"23","author":"Haleem","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s10020-022-00497-2","article-title":"Central nervous system effects of 5-HT(7) receptors: A potential target for neurodegenerative diseases","volume":"28","year":"2022","journal-title":"Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114367","DOI":"10.1016\/j.bbr.2023.114367","article-title":"Serotonin in synucleinopathies","volume":"445","author":"Hsam","year":"2023","journal-title":"Behav. Brain Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","article-title":"Serotonergic Approaches in Parkinson\u2019s Disease: Translational Perspectives, an Update","volume":"8","author":"Huot","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_18","first-page":"2023","article-title":"Serotonin Receptors as a Potential Target in the Treatment of Alzheimer\u2019s Disease","volume":"88","author":"Eremin","year":"2023","journal-title":"Biochemistry"},{"key":"ref_19","unstructured":"Ohno, Y., Tatara, A., Shimizu, S., and Sasa, M. (2012). Management of cognitive impairments in schizophrenia: The therapeutic role of 5-HT receptors. Schizophrenia Research: Recent Advances, Nova Science Publishers, Inc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"P5-HT1A receptors in mood and anxiety: Recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Leonardo","year":"2014","journal-title":"Psychopharmacology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2014.08.065","article-title":"Serotonin controlling feeding and satiety","volume":"277","author":"Voigt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tins.2006.12.002","article-title":"5-Hydroxytryptamine in premature ejaculation: Opportunities for therapeutic intervention","volume":"30","author":"Giuliano","year":"2007","journal-title":"Trends Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(97)01055-8","article-title":"Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig","volume":"331","author":"Hagan","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00003495-199855020-00002","article-title":"5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy","volume":"55","author":"Gregory","year":"1998","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5056\/jnm.2014.20.1.17","article-title":"The 5-hydroxytryptamine 4 Receptor Agonist-induced Actions and Enteric Neurogenesis in the Gut","volume":"20","author":"Takaki","year":"2014","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1742-1241.2002.tb11190.x","article-title":"Tegaserod: A novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome","volume":"56","author":"Beglinger","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"ref_28","first-page":"157","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Aguiar, R.P., Newman-Tancredi, A., Prickaerts, J., and Oliveira, R.M.W. (2021). The 5-HT(1A) receptor as a serotonergic target for neuroprotection in cerebral ischemia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 109.","DOI":"10.1016\/j.pnpbp.2020.110210"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: Signaling to behavior","volume":"161","author":"Albert","year":"2019","journal-title":"Biochimie"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1073858404267382","article-title":"5-HT1A receptors, gene repression, and depression: Guilt by association","volume":"10","author":"Albert","year":"2004","journal-title":"Neuroscientist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"s51","DOI":"10.1185\/0300799039117016","article-title":"Naratriptan","volume":"17","author":"Massiou","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1468-2982.2004.00636.x","article-title":"Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B\/1D) receptors in the cat: Implications for migraine therapy","volume":"24","author":"Boers","year":"2004","journal-title":"Cephalalgia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/00003495-200666060-00018","article-title":"Sumatriptan fast-disintegrating\/rapid-release tablets","volume":"66","author":"Moen","year":"2006","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Weisstaub","year":"2007","journal-title":"Neuron"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbamcr.2010.08.010","article-title":"Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors","volume":"1803","author":"Lukasiewicz","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-12-397220-0.00008-8","article-title":"Risperidone","volume":"37","author":"Germann","year":"2012","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_41","first-page":"666","article-title":"[Olanzapine]","volume":"71","author":"Nagai","year":"2013","journal-title":"Nihon Rinsho"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.1995.tb14977.x","article-title":"The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: Comparison with 5-HT2A and 5-HT2C receptors","volume":"115","author":"Bonhaus","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2017.07.014","article-title":"The central serotonin(2B) receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research","volume":"181","author":"Devroye","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"107417","DOI":"10.1016\/j.pharmthera.2019.107417","article-title":"Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential","volume":"205","author":"Higgins","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.2174\/138161206778522029","article-title":"5-HT3 receptors","volume":"12","author":"Thompson","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron clinical pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2165\/11202780-000000000-00000","article-title":"Transdermal granisetron","volume":"69","author":"Duggan","year":"2009","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/CE.S65555","article-title":"Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: An evidence-based review of safety, efficacy, and place in therapy","volume":"10","author":"Celio","year":"2015","journal-title":"Core Evid."},{"key":"ref_49","first-page":"23","article-title":"The role of 5-HT3-like receptors in the action of clozapine","volume":"55","author":"Wang","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"ref_50","unstructured":"(2012). Serotonin 5-HT4 Receptor Agonists. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1568007043482615","article-title":"5-HT4 receptors","volume":"3","author":"Bockaert","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_52","first-page":"Cd002300","article-title":"Cisapride treatment for gastro-oesophageal reflux in children","volume":"2010","author":"Maclennan","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00003495-200868070-00007","article-title":"Mosapride in gastrointestinal disorders","volume":"68","author":"Curran","year":"2008","journal-title":"Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.2174\/13816128113196660734","article-title":"Serotonin 5-HT4 receptors: A new strategy for developing fast acting antidepressants?","volume":"20","author":"Vidal","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1567205043332252","article-title":"New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer\u2019s disease?","volume":"1","author":"Maillet","year":"2004","journal-title":"Curr. Alzheimer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1568007043482606","article-title":"5-HT5 receptors","volume":"3","author":"Nelson","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568007043482561","article-title":"5-ht6 receptors","volume":"3","author":"Woolley","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acs.molpharmaceut.5b00830","article-title":"AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer\u2019s Disease","volume":"13","author":"Ivachtchenko","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_59","first-page":"210","article-title":"Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System","volume":"16","author":"Jaime","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1515\/revneuro-2013-0066","article-title":"Serotonergic 5-HT7 receptors and cognition","volume":"25","author":"Gasbarri","year":"2014","journal-title":"Rev. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cns.12247","article-title":"Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders","volume":"20","author":"Naumenko","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1515\/revneuro-2014-0016","article-title":"The role of serotonin 5-HT7 receptor in regulating sleep and wakefulness","volume":"25","author":"Monti","year":"2014","journal-title":"Rev. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neulet.2006.12.054","article-title":"The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder","volume":"414","author":"Hedlund","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","article-title":"Vortioxetine: Clinical Pharmacokinetics and Drug Interactions","volume":"57","author":"Chen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.2147\/DDDT.S366769","article-title":"Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy","volume":"17","author":"Miura","year":"2023","journal-title":"Drug Des. Devel Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e22235","DOI":"10.1002\/syn.22235","article-title":"Decreased 5-HT(1A) binding in mild Alzheimer\u2019s disease-A positron emission tomography study","volume":"76","author":"Mattsson","year":"2022","journal-title":"Synapse"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"128ra41","DOI":"10.1126\/scitranslmed.3003391","article-title":"Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts","volume":"4","author":"Politis","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/YPG.0b013e3282f08a06","article-title":"SERT Ileu425Val in autism, Asperger syndrome and obsessive-compulsive disorder","volume":"18","author":"Wendland","year":"2008","journal-title":"Psychiatr. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1523\/JNEUROSCI.23-25-08788.2003","article-title":"Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide","volume":"23","author":"Lemonde","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1152\/jn.00152.2002","article-title":"Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity","volume":"88","author":"Ying","year":"2002","journal-title":"J. Neurophysiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1749-6632.2001.tb05830.x","article-title":"Plasticity of the hippocampus: Adaptation to chronic stress and allostatic load","volume":"933","author":"McEwen","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_72","first-page":"394","article-title":"How to increase serotonin in the human brain without drugs","volume":"32","author":"Young","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","article-title":"Classification and basic pathology of Alzheimer disease","volume":"118","author":"Duyckaerts","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1523\/JNEUROSCI.1269-16.2016","article-title":"Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer\u2019s Amyloid-\u03b2 Oligomers in Mice","volume":"36","author":"Ledo","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Areosa, S.A., Sherriff, F., and McShane, R. (2005). Memantine for dementia. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD003154.pub3"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/1567205016666190321163438","article-title":"Therapeutic Strategies Targeting Amyloid-\u03b2 in Alzheimer\u2019s Disease","volume":"16","author":"Pinheiro","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Shi, M., Chu, F., Zhu, F., and Zhu, J. (2022). Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer\u2019s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.870517"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease","volume":"40","author":"Abdin","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JAD-190465","article-title":"In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice","volume":"73","author":"Davidowitz","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"113320","DOI":"10.1016\/j.ejmech.2021.113320","article-title":"Alzheimer\u2019s disease and its treatment by different approaches: A review","volume":"216","author":"Srivastava","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., Gonz\u00e1lez-Acedo, A., Rivas-Dom\u00ednguez, A., Garc\u00eda-Morales, V., Garc\u00eda-Cozar, F.J., Ramos-Rodr\u00edguez, J.J., and Melguizo-Rodr\u00edguez, L. (2022). Therapeutic Approach to Alzheimer\u2019s Disease: Current Treatments and New Perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061117"},{"key":"ref_83","first-page":"9343514","article-title":"Aducanumab Therapy to Treat Alzheimer\u2019s Disease: A Narrative Review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3233\/JAD-220262","article-title":"Making the Case for Accelerated Withdrawal of Aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Gunawardena, I.P.C., Retinasamy, T., and Shaikh, M.F. (2021). Is Aducanumab for LMICs? Promises and Challenges. Brain Sci., 11.","DOI":"10.3390\/brainsci11111547"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchemneu.2019.01.008","article-title":"Protective effects of 5-HT(1A) receptor antagonist and 5-HT(2A) receptor agonist on the biochemical and histological features in a rat model of Alzheimer\u2019s disease","volume":"96","author":"Afshar","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e13286","DOI":"10.1111\/acel.13286","article-title":"Antiallergic drug desloratadine as a selective antagonist of 5HT(2A) receptor ameliorates pathology of Alzheimer\u2019s disease model mice by improving microglial dysfunction","volume":"20","author":"Lu","year":"2021","journal-title":"Aging Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/00001756-199406020-00018","article-title":"5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex","volume":"5","author":"Consolo","year":"1994","journal-title":"Neuroreport"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.expneurol.2006.07.021","article-title":"Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival","volume":"203","author":"Cho","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_90","first-page":"287","article-title":"Psychedelics as Novel Therapeutics in Alzheimer\u2019s Disease: Rationale and Potential Mechanisms","volume":"56","author":"Darcy","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.22662.1","article-title":"New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer\u2019s disease: Focus on brexpiprazole and pimavanserin","volume":"9","author":"Caraci","year":"2020","journal-title":"F1000Res"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2017.07.010","article-title":"Antagonism of the 5-HT(6) receptor\u2014Preclinical rationale for the treatment of Alzheimer\u2019s disease","volume":"125","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"111596","DOI":"10.1016\/j.ejmech.2019.111596","article-title":"Novel multi target-directed ligands targeting 5-HT(4) receptors with in cellulo antioxidant properties as promising leads in Alzheimer\u2019s disease","volume":"182","author":"Lanthier","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1289\/ehp.1306967","article-title":"Research on the premotor symptoms of Parkinson\u2019s disease: Clinical and etiological implications","volume":"121","author":"Chen","year":"2013","journal-title":"Environ. Health Perspect."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00702-015-1405-5","article-title":"Neuropathobiology of non-motor symptoms in Parkinson disease","volume":"122","author":"Jellinger","year":"2015","journal-title":"J. Neural Transm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.pbr.2020.11.001","article-title":"Serotonergic imaging in Parkinson\u2019s disease","volume":"261","author":"Wilson","year":"2021","journal-title":"Prog. Brain Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/brain\/awx376","article-title":"Progression of tremor in early stages of Parkinson\u2019s disease: A clinical and neuroimaging study","volume":"141","author":"Pasquini","year":"2018","journal-title":"Brain"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: A special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/mds.27216","article-title":"Levodopa: A new look at an old friend","volume":"33","author":"Olanow","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1755-5949.2010.00211.x","article-title":"Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson\u2019s disease","volume":"17","author":"Ohno","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","article-title":"5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson\u2019s disease","volume":"23","author":"Bezard","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"108693","DOI":"10.1016\/j.neuropharm.2021.108693","article-title":"Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease are counteracted by combined administration of a 5-HT(1A\/1B) receptor agonist and A(2A) receptor antagonist","volume":"196","author":"Pinna","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bph.14076","article-title":"5-HT(1F) receptor-mediated mitochondrial biogenesis for the treatment of Parkinson\u2019s disease","volume":"175","author":"Scholpa","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2174\/0929867323666160122115057","article-title":"Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson\u2019s Disease","volume":"23","author":"Miyazaki","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acschemneuro.8b00618","article-title":"Dual 5-HT(6) and D(3) Receptor Antagonists in a Group of 1H-Pyrrolo[3,2-c]quinolines with Neuroprotective and Procognitive Activity","volume":"10","author":"Grychowska","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2007.12.032","article-title":"Neuroprotective effects of serotonin 5-HT 1A receptor activation against ischemic cell damage in gerbil hippocampus: Involvement of NMDA receptor NR1 subunit and BDNF","volume":"1199","author":"Frechilla","year":"2008","journal-title":"Brain Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kwon, D.K., Kwatra, M., Wang, J., and Ko, H.S. (2022). Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease: Pathogenesis and Emerging Treatment Strategies. Cells, 11.","DOI":"10.3390\/cells11233736"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"116869","DOI":"10.1016\/j.jns.2020.116869","article-title":"Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson\u2019s disease: A preliminary finding","volume":"415","author":"Meloni","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Choi, Y., Huh, E., Lee, S., Kim, J.H., Park, M.G., Seo, S.Y., Kim, S.Y., and Oh, M.S. (2023). 5-Hydroxytryptophan Reduces Levodopa-Induced Dyskinesia via Regulating AKT\/mTOR\/S6K and CREB\/\u0394FosB Signals in a Mouse Model of Parkinson\u2019s Disease. Biomol. Ther., 31.","DOI":"10.4062\/biomolther.2022.141"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2010.03.013","article-title":"5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson\u2019s disease","volume":"59","author":"Ferguson","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"172914","DOI":"10.1016\/j.ejphar.2020.172914","article-title":"Ondansetron, a highly selective 5-HT(3) receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease","volume":"871","author":"Kwan","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pbb.2005.03.012","article-title":"Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets","volume":"81","author":"Osinski","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2013.10.014","article-title":"Looking beyond 5-HT(3) receptors: A review of the wider role of serotonin in the pharmacology of nausea and vomiting","volume":"722","author":"Johnston","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1007\/s00415-004-1606-6","article-title":"Depression and Parkinson\u2019s disease","volume":"251","author":"Lemke","year":"2004","journal-title":"J. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2174\/1570159X18666201015155816","article-title":"5-HT(3) receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders","volume":"19","author":"Bhatt","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pbb.2015.05.001","article-title":"Aggression and anxiety in adolescent AAS-treated hamsters: A role for 5HT3 receptors","volume":"134","author":"Morrison","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT(2A) antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FBP.0b013e32834aff98","article-title":"Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson\u2019s disease","volume":"22","author":"McFarland","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","article-title":"Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson\u2019s disease psychosis patients","volume":"87","author":"Isaacson","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.4103\/0028-3886.359257","article-title":"Neuropathic Pain in Parkinson\u2019s Disease","volume":"70","author":"Bandala","year":"2022","journal-title":"Neurol. India"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1007\/s12035-022-03034-8","article-title":"Inhibition of Spinal 5-HT3 Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson\u2019s Disease","volume":"59","author":"Li","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"8659462","DOI":"10.1155\/2022\/8659462","article-title":"Electroacupuncture Modulates 5-HT(4R)-Mediated cAMP\/PKA Signaling to Improve Intestinal Motility Disorders in a Thy1-\u03b1Syn Parkinson\u2019s Mouse Model","volume":"2022","author":"Shen","year":"2022","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Liu, T., Song, J., Zhou, Q., Chu, S., Liu, Y., Zhao, X., Ma, Z., Xia, T., and Gu, X. (2022). The role of 5-HT(7)R in the memory impairment of mice induced by long-term isoflurane anesthesia. Neurobiol. Learn. Mem., 188.","DOI":"10.1016\/j.nlm.2022.107584"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Roux, C.M., Leger, M., and Freret, T. (2021). Memory Disorders Related to Hippocampal Function: The Interest of 5-HT(4)Rs Targeting. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222112082"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00210-023-02411-x","article-title":"The role of hippocampal 5-HT(1D) and 5-HT(1F) receptors on learning and memory in rats","volume":"396","author":"Afshar","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/00207450600754087","article-title":"Serotonergic mechanisms in amyotrophic lateral sclerosis","volume":"116","author":"Sandyk","year":"2006","journal-title":"Int. J. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Martin, E., Cazenave, W., Allain, A.E., Cattaert, D., and Branchereau, P. (2020). Implication of 5-HT in the Dysregulation of Chloride Homeostasis in Prenatal Spinal Motoneurons from the G93A Mouse Model of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031107"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"ENEURO.0001-22.2022","DOI":"10.1523\/ENEURO.0001-22.2022","article-title":"Distribution Features and Potential Effects of Serotonin in the Cerebrum of SOD1 G93A Transgenic Mice","volume":"9","author":"He","year":"2022","journal-title":"eNeuro"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1046\/j.1460-9568.1998.00248.x","article-title":"Serotonin inhibits synaptic glutamate currents in rat nucleus accumbens neurons via presynaptic 5-HT1B receptors","volume":"10","author":"Muramatsu","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/157015906776359540","article-title":"Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: Implications in physiological functions and in pathology","volume":"4","author":"Ciranna","year":"2006","journal-title":"Curr. Neuropharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-016-1534-4","article-title":"Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis","volume":"131","author":"Bayer","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Arnoux, A., Ayme-Dietrich, E., Dieterle, S., Goy, M.A., Schann, S., Frauli, M., Monassier, L., and Dupuis, L. (2021). Evaluation of a 5-HT(2B) receptor agonist in a murine model of amyotrophic lateral sclerosis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02900-0"},{"key":"ref_143","first-page":"2047","article-title":"5-Hydroxytryptamine: A potential therapeutic target in amyotrophic lateral sclerosis","volume":"18","author":"Jiang","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_144","first-page":"28","article-title":"Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathways","volume":"4","author":"Lam","year":"2015","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/MIB.0000000000000150","article-title":"Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract","volume":"20","author":"Guseva","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14660820310009389","article-title":"The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis","volume":"4","author":"Turner","year":"2003","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/brain\/aws274","article-title":"Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: A link to spasticity","volume":"136 Pt. 2","author":"Dentel","year":"2013","journal-title":"Brain"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.25030","article-title":"Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis","volume":"82","author":"Vercruysse","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"104949","DOI":"10.1016\/j.phrs.2020.104949","article-title":"Role of 5-HT receptors in neuropathic pain: Potential therapeutic implications","volume":"159","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11910-020-01047-1","article-title":"Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis","volume":"20","author":"Boentert","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","article-title":"Serotonin control of sleep-wake behavior","volume":"15","author":"Monti","year":"2011","journal-title":"Sleep Med. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0194599819846109","article-title":"Mice Lacking Brain-Derived Serotonin Have Altered Swallowing Function","volume":"161","author":"Haney","year":"2019","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Dupuis, L., Spreux-Varoquaux, O., Bensimon, G., Jullien, P., Lacomblez, L., Salachas, F., Bruneteau, G., Pradat, P.F., Loeffler, J.P., and Meininger, V. (2010). Platelet serotonin level predicts survival in amyotrophic lateral sclerosis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013346"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of Huntington\u2019s disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1172\/JCI17742","article-title":"Huntingtin in health and disease","volume":"111","author":"Young","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3233\/JHD-180318","article-title":"Increased Serotonin Transporter Expression in Huntington\u2019s Disease Patients Is Not Consistently Replicated in Murine Models","volume":"8","author":"He","year":"2019","journal-title":"J. Huntingt. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0304-3940(87)90639-2","article-title":"Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington\u2019s disease brain","volume":"78","author":"Reynolds","year":"1987","journal-title":"Neurosci. Lett."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.parkreldis.2011.05.012","article-title":"Serotonin and dopamine striatal innervation in Parkinson\u2019s disease and Huntington\u2019s chorea","volume":"17","author":"Wallman","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55782\/ane-2006-1581","article-title":"Role of serotonin in cerebral oxidative stress in rats","volume":"66","author":"Montilla","year":"2006","journal-title":"Acta Neurobiol. Exp."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.redox.2016.12.034","article-title":"Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB\/CREB\/BDNF pathway and Akt\/Nrf2\/Antioxidant enzyme in neuronal cells","volume":"11","author":"Yoo","year":"2017","journal-title":"Redox Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pnpbp.2006.06.021","article-title":"Perospirone in treatment of Huntington\u2019s disease: A first case report","volume":"31","author":"Roppongi","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington\u2019s disease","volume":"18","author":"Pang","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The Roles of Serotonin in Neuropsychiatric Disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Nedic Erjavec, G., Tudor, L., Nikolac Perkovic, M., Podobnik, J., Dodig Curkovic, K., Curkovic, M., Svob Strac, D., Cusek, M., Bortolato, M., and Pivac, N. (2022). Serotonin 5-HT(2A) receptor polymorphisms are associated with irritability and aggression in conduct disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 117.","DOI":"10.1016\/j.pnpbp.2022.110542"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mcp.2010.04.006","article-title":"The genetics of multiple sclerosis: An update 2010","volume":"24","author":"Hoffjan","year":"2010","journal-title":"Mol. Cell. Probes"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.autrev.2009.02.009","article-title":"The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis","volume":"8","author":"Smolders","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"77","DOI":"10.17116\/jnevro201811808277","article-title":"Interferon-induced depression and peripheral blood serotonin in patients with multiple sclerosis","volume":"118","author":"Baidina","year":"2018","journal-title":"Zh Nevrol. Psikhiatr Im. S S Korsakova"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Reverchon, F., Guillard, C., Mollet, L., Auzou, P., Gosset, D., Madouri, F., Val\u00e9ry, A., Menuet, A., Ozsancak, C., and Pallix-Guyot, M. (2022). T Lymphocyte Serotonin 5-HT(7) Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102418"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp-2013-306829","article-title":"Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: Systematic review and meta-analysis","volume":"85","author":"Foley","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"577608","DOI":"10.1016\/j.jneuroim.2021.577608","article-title":"The role of 5-HT(2B)-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis","volume":"356","author":"Sviridova","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/7854_2014_288","article-title":"Mechanisms and pharmacology of neuropathic pain in multiple sclerosis","volume":"20","author":"Iannitti","year":"2014","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40263-022-00914-4","article-title":"Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies","volume":"36","author":"Gurba","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/jn.00774.2010","article-title":"Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity","volume":"105","author":"Murray","year":"2011","journal-title":"J. Neurophysiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1352458515588973","article-title":"Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis","volume":"22","author":"Hoang","year":"2016","journal-title":"Mult. Scler."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1136\/jnnp.2004.060426","article-title":"Depression in neurological disorders: Parkinson\u2019s disease, multiple sclerosis, and stroke","volume":"76","author":"Rickards","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458518770021","article-title":"Polymorphism in the serotonin transporter gene polymorphisms (5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis","volume":"25","author":"Saul","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF00711237","article-title":"Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer\u2019s disease: A postmortem study","volume":"12","author":"Nazarali","year":"1992","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Babi\u0107 Leko, M., Nikolac Perkovi\u0107, M., \u0160pani\u0107, E., \u0160vob \u0160trac, D., Plei\u0107, N., Vogrinc, \u017d., Gunja\u010da, I., Be\u017eovan, D., Nedi\u0107 Erjavec, G., and Klepac, N. (2022). Serotonin Receptor Gene Polymorphisms Are Associated with Cerebrospinal Fluid, Genetic, and Neuropsychological Biomarkers of Alzheimer\u2019s Disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123118"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.parkreldis.2015.05.016","article-title":"Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson\u2019s disease are associated with nonmotor symptoms","volume":"21","author":"Tong","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","article-title":"Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease","volume":"14","author":"Guttman","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","article-title":"Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease","volume":"31","author":"Cheng","year":"2016","journal-title":"J. Nutr. Biochem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:52:36Z","timestamp":1760115156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":183,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252413446"],"URL":"https:\/\/doi.org\/10.3390\/ijms252413446","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,15]]}}}